IMCA treatment reduces CRC cell viability in vitro, inhibits the growth of xenografted CRC cells in vivo, and is associated with a decrease in the phosphorylation of mTOR and its downstream target P70S6K (125). The gene discussed is RPS6KB1; the disease is colorectal carcinoma.